Bioequivalence Debate: ViroPharma Will Defend Vancocin At Advisory Cmte.
Executive Summary
ViroPharma's Vancocin (vancomycin) isn't specifically on the agenda at the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee, but the firm is treating the panel as a make-or-break event for the colitis treatment
You may also be interested in...
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.
“Difficult” Bioequivalence Issues Make Limited Progress At Advisory Cmte.
If the July 23 meeting of the Pharmaceutical Science and Clinical Pharmacology Advisory Committee is any indication, FDA appears years away from changing approval standards for generics of drugs with complex dosage forms.
Licensing Deals Rake In Upfront $100+ Million For Drug Developers
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the In Vivo blog. Visit the blog at http://invivoblog.blogspot.com/.